CELL AND GENE THERAPY
Fulgent Genetics, Inc. | February 24, 2022
Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Capital and other investors. Fulgent is also entering into commercial arrangements with Spatial to integrate Spatial Genomics’ seqFISH technology into Fulgent’s comprehensive genomic testing platform.
Spatial Genomics has developed a spatial single-cell multiomics analysis platform based on the seqFISH technology originally developed in the laboratory of Professor Long Cai at the California Institute of Technology. seqFISH is a revolutionary technology designed to enable highly multiplexed and multiomic analyses of cells directly in the tissue microenvironments where they function, allowing researchers to identify novel cell types and cellular interactions, map genomic organization and nuclear architecture, and analyze cell trajectories far more efficiently than existing technologies.
Under this arrangement, Fulgent expects to add Spatial Genomics’ multiomics analysis platform to the suite of lab services already available to its pharmaceutical and clinical research customer base.
“We believe this strategic investment and commercial arrangement is an exciting opportunity for Fulgent as we will add Spatial Genomics’ leading seqFISH technology and multiomics analysis platform to our suite of genomic testing solutions. Spatial’s seqFISH technology is a highly promising platform that will enable clinicians to efficiently perform highly multiplexed single-cell analysis of RNA, DNA and proteins beyond the capabilities of other types of spatial analyses. We look forward to working with Spatial to commercialize this technology for broader reach and application.”
Dr. Harry Gao, Chief Scientific Officer at Fulgent
“We are excited to secure this Series A funding, which will support and accelerate our continued growth as a company, and the ongoing commercialization of our seqFISH technology platform,” said Kirsten Frieda, CEO and cofounder of Spatial Genomics. “seqFISH enables a highly multiplexed, quantitative, and multiomic analysis of cells and tissues that we believe will be essential to the next era of biological discovery, the continued evolution of precision medicine, drug and biomarker discovery, and the improvement of clinical diagnostics.”
Spatial Genomics will use the funds from its Series A financing round to accelerate the commercialization of their seqFISH technology platform, grow their seqFISH laboratory services group, and aggressively expand their workforce, including in R&D, engineering, manufacturing, sales, marketing, customer support, and commercial operations.
About Fulgent Genetics
Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service, and automated lab services.
About Spatial Genomics
Spatial Genomics is a biology and life science technology company dedicated to empowering discovery. Spatial Genomics’ integrated technology platform consists of instrumentation, reagents, and software and is being developed with a vision of providing the highest possible multiplexity of multi-omic biological analysis capabilities. Our highly multiplexed spatial analysis technology will advance fundamental biology, precision medicine, drug and biomarker discovery, and lead to the improvement of clinical diagnostics.
CELL AND GENE THERAPY
IsoPlexis | May 26, 2021
IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell.
This is the next step in the company's roadmap, enabling researchers to make far earlier connections in their genomic studies, straight to the proteome, which determines each organism's in vivo dynamic biology. The acquired assets will allow IsoPlexis' proprietary proteomics technologies to be integrated with newer proprietary sequencing-based technologies. The asset acquisition adds to IsoPlexis' ongoing efforts to assist its customers in more effectively simplifying complex biology to accelerate the creation of more personalized and curative advanced medicines from bench to bedside.
Isoplexis' growing patent portfolio of 153 total patents filed and issued globally will now include sequencing methodologies, allowing for a new level of resolution into the connections between the genome and the proteome of cancer immunology, cell and gene therapy, neurological disease, and other areas.
IsoPlexis' proprietary functional proteomics platform is the first to fully characterize and link cellular function to patient outcomes, treatment response, or disease progression using both proteomics and single-cell biology. The single-cell proteomics platform from IsoPlexis, which comprises instruments, chip consumables, and software, offers an end-to-end solution for providing a more complete view of protein function at the cellular level.
The platform has been quickly embraced by the top 15 global biopharmaceutical companies in terms of revenue, as well as over half of the comprehensive cancer centers in the United States, to develop more durable therapeutics, overcome therapeutic resistance, and predict patient responses for advanced immunotherapies, cell therapies, gene therapies, vaccines, and regenerative medicines.
IsoPlexis is a life science technology company that develops solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect to in vivo biology more directly and develop more precise and personalized therapies. Our integrated systems, which were named top innovation or design by Scientist Magazine, Fierce, BIG Innovation, Red Dot, and a variety of other magazines, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been used by researchers all over the world, including the top 15 pharmaceutical companies in the world and 45% of comprehensive cancer centers in the United States.
MindMed | January 21, 2021
MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland.
If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and nervousness that are sometimes associated with LSD - creating a general more good experience.
MindMed is undertaking a Phase 1 clinical preliminary to assess if MDMA, when adjusted and utilized in combination with LSD, can help offset a portion of the known expected horrendous impacts of LSD that happen in treatment or clinical settings. MindMed is keen on arrangement how to adjust both MDMA and LSD in a strong manner to make better patient results, and grow further developed hallucinogenic helped treatments, as MindMed extends the two its R&D and commercial drug improvement pipeline. The examination is foreseen to take around one year to finish.